Cargando…
Priorities for the Priority Review Voucher
The U.S. Congress created the priority review voucher program in 2007 to encourage development of drugs for neglected diseases. Under the voucher program, the developer of a drug for a neglected or rare pediatric disease that is approved by the U.S. Food and Drug Administration receives a bonus prio...
Autor principal: | Ridley, David B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Tropical Medicine and Hygiene
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239680/ https://www.ncbi.nlm.nih.gov/pubmed/27573624 http://dx.doi.org/10.4269/ajtmh.16-0600 |
Ejemplares similares
-
The Tropical Disease Priority Review Voucher: A Game-Changer for Tropical Disease Products
por: Berman, Jonathan, et al.
Publicado: (2017) -
Ebola Outbreak amid COVID-19 in the Republic of Guinea: Priorities for Achieving Control
por: Aborode, Abdullahi Tunde, et al.
Publicado: (2021) -
Priority Review Vouchers: GAO Report Provides Scant Evidence of Success
por: Meyer, Robert J.
Publicado: (2020) -
Clinical Research and the Training of Host Country Investigators: Essential Health Priorities for Disease-Endemic Regions
por: Koita, Ousmane A., et al.
Publicado: (2016) -
Responding to the Challenge of the Dual COVID-19 and Ebola Epidemics in the Democratic Republic of Congo—Priorities for Achieving Control
por: Nachega, Jean B., et al.
Publicado: (2020)